Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425 | Completed Phase 3

• 1 other identifier: 051-308
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 5

Brief Summary

The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma

Conditions

Asthma; Bronchoconstriction

Keywords

Asthma; Exercised induced bronchoconstriction

Outcome Measures

Primary Outcomes (1)

• FEV1 AUC 0-60 (% decrease from post-dose/pre-challenge FEV1)

  Days -7, 0, 5, 10, 15

Secondary Outcomes (9)

• Maximum percent decrease in FEV1 from visit post-dose/pre-challenge FEV1

  Days -7, 0, 5, 10, 15

• Minimum percent change in FEV1 from visit pre-dose FEV1.

  Days -7, 0, 5, 10, 15

• time to recovery (min), Protected/Unprotected Subjects Counts

  Days -7, 0, 5, 10, 15

• FVC AUC 0-60 (% decrease from post-dose/pre-challenge FEV1).

  Days -7, 0, 5, 10, 15

• Maximum percent decrease in FVC from visit post-dose/pre-challenge FVC,

  Days -7, 0, 5, 10, 15

Study Arms (2)

A

EXPERIMENTAL

Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.

Drug: Levalbuterol HFA MDI

B

ACTIVE COMPARATOR

Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.

Drug: Racemic Albuterol

Interventions

Levalbuterol HFA MDI DRUG

1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). 2. Arm #A 3. Xopenex HFA MDI

A

Racemic Albuterol DRUG

1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). 2. Arm #B 3. Proventil HFA MDI

B

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject, male or female, must be at least 12 years of age at the time of consent.
• Female subjects 12-60 years of age must have a negative serum pregnancy test.
• Women of child bearing potential must be using an acceptable method of birth control throughout the study.
• Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start
• Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.
• Subject must have a chest X-ray for the study or within 12 months prior to randomization.
• Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.

You may not qualify if:

• Female subject who is pregnant or lactating.
• Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.
• Subject whose schedule prevents him or her from starting study visits before 12 PM.
• Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.
• Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.
• Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.
• Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.
• Subject using any prescription drug with which albuterol sulfate administration is contraindicated.
• Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.
• Subject with a history of cancer (exception: basal cell carcinoma in remission).
• Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.
• Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.
• Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.
• Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.
• Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.

Sponsors & Collaborators

• Sumitomo Pharma America, Inc.: lead

Study Sites (5)

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Signal Hill, California, United States

Location

Unknown Facility

Denver, Colorado, United States

Location

Unknown Facility

Minneapolis, Minnesota, United States

Location

Unknown Facility

Burke, Virginia, United States

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 23, 2008
• First Posted: May 28, 2008
• Study Start: October 1, 2002
• Primary Completion: March 1, 2003
• Study Completion: March 1, 2003
• Last Updated: February 22, 2012

Record last verified: 2012-02

Locations

US (5)